Viewpoints

Misleading the public about their investments-be it money or medicine-is unacceptable.

Follow-on biologics could unleash the potential of several industries and may even spark economic recovery.

Short-term problems in software or hardware lead to long-term manufacturing troubles.

The president of BIO proposes the ingredients needed for industry growth.

Process steps, GMP documents, a purification vessel, and validation seem to disappear.

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.

Obama's cost-containment and science-innovation initiatives need to overlap.

The financial and economic downturn is likey to have long-term implications for outsourcing.

The role of automation suppliers is transforming to meet the pharma industry's demand for change.

GMP agents report on old products, aseptic violations, and unexpected emotions.

USP's revised chapter on injectables could harm anticounterfeiting efforts and drug administration.

The source of a problem reveals itself after some investigation, or it may crash down on you.

GMP experts act fast to resolve some unusual and difficult problems.

To manage risk properly, industry must understand what it is and how to assess it

FDA's role should not be overlooked as it has been in years past.

During the last 20 years, pharmaceutical R&D spending has increased 15-fold while new product approvals have increased only 0.70-fold.

The incoming administration has renewed hope for stem cells, but less adequate copycats may follow.

President Obama's choice for agency leadership should take into account several factors.

Readers give advice on their best approach to handling (batch) rejection

When accusations fly: 'Tis better to give than to receive.

The past year saw major acquisitions attempted, completed, rejected, and stalled.

Readers provide insight into the best companies to work for as well as the ups and downs of their jobs.

China's quality approach to domestic versus exported products seems to be a lose-lose situation.

Data capture needs to be fast and reliable...so which automatic identification technology is best?

Pharma companies could benefit from the lessons learned in this fall's financial crisis.

Production problems come in all shapes, sizes, and ... species.

Industry needs a standard to connect systems and equipment sooner rather than later.

To err may be human, but to really mess things up, you need management.

Can previous trends of Democratic and Republican administrations predict industry's future?

This year, the employment survey will acknowledge the industry's best employers.